Nano Pharmaceuticals

Colinz Laboratories Ltd.

COLINZ

Market Cap
₹19 Cr.
P/E
36.18

Colinz Laboratories Ltd.

  • Colinz Laboratories
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

FAQs on Colinz Laboratories Ltd. Shareprice

Colinz Laboratories has given better returns compared to its competitors.
Colinz Laboratories has grown at ~30.83% over the last 6yrs while peers have grown at a median rate of 27.19%

Yes, Colinz Laboratories is expensive.
Latest PE of Colinz Laboratories is 38.08, while 3 year average PE is 26.79.
Also latest EV/EBITDA of Colinz Laboratories is 29.07 while 3yr average is 11.28.

View FAQ's On Business

Growth Table

  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Balance Sheet

  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Cash Flow

  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Quarterly Results

  • Colinz Laboratories Ltd.
  • Desh Rakshak Aushdh
  • Rekvina Laboratories

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Colinz Laboratories Ltd. Financials

Balance sheet of Colinz Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Colinz Laboratories is increasing.
Latest net debt of Colinz Laboratories is -₹8.14 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹10.45 Crs.

Yes, profit is increasing.
The profit of Colinz Laboratories is ₹0.51 Crs for TTM, ₹0.5 Crs for Mar 2025 and ₹0.49 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Colinz Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech